Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Latest Market Insights for the Hereditary Angioedema Therapeutics Industry?
The market size of therapeutics for hereditary angioedema has seen a swift increase in the recent past. It is expected to enlarge from $6.68 billion in 2024 to $7.77 billion in 2025, witnessing a compound annual growth rate (CAGR) of 16.3%. The remarkable growth during the historical phase can be credited to factors such as enhanced diagnosis and awareness, extended accessibility of treatments, research and development efforts, as well as initiatives for patient advocacy and education, and regulatory endorsements.
Expectations are high for the hereditary angioedema therapeutics market, with rapid growth anticipated in the coming years. Its projected size by 2029 is an impressive $15.84 billion, reflecting a compound annual growth rate (CAGR) of 19.5%. This predicted growth within the forecast period is mainly due to key developments such as targeted therapies, market globalization, breakthroughs in gene therapy, advancements in personalized medicine, and research and treatment collaborations. The forecast period also carries important trends including initiatives for global access, health economic outcomes research, strategies for early intervention, and therapeutics for pediatric HAE.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp
What Forces Are Driving The Growth Of The Hereditary Angioedema Therapeutics Industry?
The increasing incidence of hereditary angioedema is projected to boost the progression of the hereditary angioedema market. Hereditary angioedema (HAE) is an uncommon genetic ailment, marked by frequent bouts of severe swelling of the skin and mucous membranes due to an excessive accumulation of fluid (EDEMA). This swelling can transpire anywhere in the body such as the hands, feet, face, intestines and airways. For example, as reported by Rare Disease Advisor, a digital resource platform catering to global healthcare professionals, in June 2022, hereditary angioedema affects roughly 1 in 50,000 individuals worldwide, with prevalence estimates varying between 1:10,000 to 1:150,000. The disease is responsible for 15,000 to 30,000 emergency room visits annually in the United States. Here 5.8% of HAE cases had an average diagnosis time duration between 0 to 6 months, while another 5.8% took over 10 years for diagnosis. As a result, this escalating occurrence of hereditary angioedema is steering the hereditary angioedema market’s expansion.
What Is The Overview Of Market Segmentation In The Hereditary Angioedema Therapeutics Industry?
The hereditary angioedema therapeutics market covered in this report is segmented –
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand
Subsegments:
1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant
2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab
4) By Other Drug Classes: Emerging Therapies
What Future Market Trends Are Projected For The Hereditary Angioedema Therapeutics Industry?
Leading product innovations are emerging as a pivotal trend in the hereditary angioedema therapeutics market. Major corporations in this area are focusing on creating ground-breaking products including ligand-conjugated (LICA) experimental antisense drugs and gene therapy to maintain their dominance. For instance, in March 2023, US-based clinical-stage biotech firm Intellia Therapeutics launched a new investigational drug, NTLA-2002, approved by the US Food and Drug Administration for treating hereditary angioedema. This approval expands the company’s ongoing Phase 1/2 trial to incorporate the US into the global Phase 2 section. Upon a single-dose administration, the target gene, Kallikrein B1 (KLKB1), is permanently inactivated, reducing plasma kallikrein protein activity and preventing HAE attacks. NTLA-2002 stands as a contender for in vivo genome editing.
Who Are The Primary Players Operating Across The Global Hereditary Angioedema Therapeutics Market?
Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.
Get The Full Report Here:
Which Region Offers The Most Growth Potential For The Hereditary Angioedema Therapeutics Market Through 2029?
North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
